Details of the Competitor

General Information of Competitor

Competitor ID
LDCM0114
Competitor Name
Len
Synonyms
Lenalidomide; 191732-72-6; Revlimid; Revimid; 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione; CC-5013; CDC 501; CDC-501; Lenalidomide (CC-5013); 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; IMiD3; CC 5013; 3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione; Lenadoamide; NSC-747972; UNII-F0P408N6V4; DTXSID8046664; CHEBI:63791; ENMD 0997; HSDB 8220; C13H13N3O3; F0P408N6V4; SYP-1512; Revlimid (TN); (3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline; DTXCID6026664; MFCD07772307; NSC 747972; NCGC00167491-01; Lenalidomide [USAN]; 3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione; LENALIDOMIDE (MART.); LENALIDOMIDE [MART.]; Revlimid (lenalidomide); 3-(4-Amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione; IMiD3 cpd; CAS-191732-72-6; Lenalidomide (USAN/INN); lenalidomidum; Lenalidomida; Lenalidomide?; Lenalidomide [USAN:INN:BAN]; 443912-14-9; ENMD-0997; IMID-5013; CDC-5013; LENALIDOMIDE [MI]; LENALIDOMIDE [INN]; LENALIDOMIDE [JAN]; CHEMBL848; Revlimid (TN) (Celgene); LENALIDOMIDE [VANDF]; SCHEMBL32978; MLS003899194; LENALIDOMIDE [WHO-DD]; GTPL7331; SCHEMBL1980410; LENALIDOMIDE [EMA EPAR]; 3-(4-Amino-1-oxo-2-isoindolinyl)piperidine-2,6-dione; SCHEMBL26646478; BDBM65454; L04AX04; 3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione; BCPP000186; HMS3654G07; HMS3674C05; LENALIDOMIDE [ORANGE BOOK]; BCP01390; HY-A0003; Revlimid, Lenalidomide, CC-5013; Tox21_112492; AC-914; NSC703813; NSC747972; s1029; STK639603; 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H- isoindol-2-yl)-; AKOS005146276; AKOS005174869; Tox21_112492_1; BCP9000847; CCG-264781; CS-0125; DB00480; KS-1207; MCULE-9771679074; SB66166; NCGC00167491-02; NCGC00167491-03; NCGC00167491-04; BL164614; BP-27972; SMR002529986; SY047646; AM20050439; NS00003666; SW218084-2; D04687; EN300-118706; AB01273975-01; AB01273975-02; AB01273975_03; Q425681; SR-01000883999; Q-101410; SR-01000883999-1; 1-Oxo-4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole; Z1515385074; 2, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-; 3-(4-amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-dioxopiperidine; 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)-2,6-piperidinedione; (3RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione; 4-amino-2-(6-hydroxy-2-oxo-2,3,4,5-tetrahydropyridin-3-yl)-2,3-dihydro-1H-isoindol-1-one
Structure
3D MOL 2D MOL
Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 259.26
Lipid-water partition coefficient (xlogp) -0.5
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
Chemical Identifiers
Formula
C13H13N3O3
IUPAC Name
3-(7-amino-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
Canonical SMILES
C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey
GOTYRUGSSMKFNF-UHFFFAOYSA-N

The Competitor Interaction Atlas

Probe(s) Related This Competitor

PAL-AfBPP Probe
Click To Hide/Show 1 Probe Related to This Competitor
Probe Name Structure Concentration Cell-system Ref
pLen
 Probe Info  		50 uM Human plasma cell myeloma cells (MM1.S) [1]

Target(s) List of this Competitor

1 Transporter and channel Competed by This Competitor
Target Name Target ID Binding Ratio Interaction ID
Protein cereblon (CRBN) LDTP10826 8.01  LDD0254 
------------------------------------------------------------------------------------
1 Transcription factor Competed by This Competitor
Target Name Target ID Binding Ratio Interaction ID
DNA-binding protein Ikaros (IKZF1) LDTP05861 6.86  LDD0254 
------------------------------------------------------------------------------------
1 Other Competed by This Competitor
Target Name Target ID Binding Ratio Interaction ID
Eukaryotic translation initiation factor 3 subunit I (EIF3I) LDTP05834 3.13  LDD0255 
------------------------------------------------------------------------------------

Full Information of The Labelling Profiles of This Competitor

Quantification: Probe vs (Probe+Competitor)
  
Experiment 1 Reporting the Labelling Profiles of This Probe
REF [1]
Probe concentration 50 uM
Quantitative Method LFQ
Competitor Name Len
Competitor Concentration 150 uM
In Vitro Experiment Model Model Type
Living cell
Derived Tissue
Peripheral blood
Disease Model Plasma cell myeloma [ICD-11:2A83]
Model Name Human plasma cell myeloma cells (MM1.S)
Interaction Atlas ID  LDD0254  Download The Altas
  
Experiment 2 Reporting the Labelling Profiles of This Probe
REF [1]
Probe concentration 50 uM
Quantitative Method LFQ
Competitor Name Len
Competitor Concentration 150 uM
In Vitro Experiment Model Model Type
Living cell
Derived Tissue
Peripheral blood
Disease Model Normal
Model Name Human normal cells (HEK-293T)
Interaction Atlas ID  LDD0255  Download The Altas

References

1 Development of Photolenalidomide for Cellular Target Identification. J Am Chem Soc. 2022 Jan 12;144(1):606-614. doi: 10.1021/jacs.1c11920. Epub 2022 Jan 3.